Muc21 a good candidate in designing new immunotoxins affecting the esophageal cancer

Esophageal cancer is the world s eighth most common cancer and the sixth most common cause of cancer death in the world. In this regard, Iran is the second country with the highest death rate due tothis cancer in the eastern part of the Middle East. In spite of multiple therapeutic approaches, treatment of this disease is one of the most difficult therapeutic challenges in oncology. However, immunotoxindrugs are promising way to targeting these types of cancer cells through detection corresponding specific antigens via ligands. Bearing in mind, associated antigens of these cells were screened in thisresearch to candidate the best antigen for immunotoxin development. Our results led to a profile of antigens including DSG3, CISD1, MUC21, LY6D, GPR171, IL17RA, IL1RAPL2, IL18R1, IL15RA, CDCP1, CDKAL1, CCR3, CISD1, DSC3, TMPRSS11D, TMPRSS11E, ZDHHC7, DYNAP, CLCA2, DSG3, ERBB2, FUT3, SLC10A6, C7ORF60, C18ORF32, BTNL9, BCAP29, APLF, ANO2, ADORA3, CCR3, CD44, ADORA3 was developed. Nonetheless, in-silico expression assay of these antigens reveal significance data, so that among them MUC21 showed highest and widespread expression on the cells surface of skin, vagina, cervix and especially esophagus malignancy cells. On the other hand, corresponding ligands of this antigen based STRING investigation reveal a series of proteins that confirmed by molecular docking. Taken together this study introducing MUC21 as a good candidate for diagnosis as well as candidate for immunotoxin development for esophagus cancers.

کلیدواژه ها:

Gene and Cancer ، Cancer Genetics ، Cancer Treatment and Management ، Targeted Cancer Therapy ، Drugs and Cancer